These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 29080222)

  • 1. Free fatty acid receptor 1 agonist, MR1704, lowers blood glucose levels in rats unresponsive to the sulfonylurea, glibenclamide.
    Tsuda N; Kawaji A; Takagi M; Higashi C; Nakamura M; Hosaka Y; Sakaki J
    Drug Dev Res; 2018 Feb; 79(1):16-21. PubMed ID: 29080222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
    Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
    J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.
    Tsuda N; Kawaji A; Sato T; Takagi M; Higashi C; Kato Y; Ogawa K; Naba H; Ohkouchi M; Nakamura M; Hosaka Y; Sakaki J
    Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
    Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
    PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic activity and toxicity of Zizyphus spina-christi leaves.
    Abdel-Zaher AO; Salim SY; Assaf MH; Abdel-Hady RH
    J Ethnopharmacol; 2005 Oct; 101(1-3):129-38. PubMed ID: 16009520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat.
    Ohyama S; Takano H; Iino T; Nishimura T; Zhou YP; Langdon RB; Zhang BB; Eiki J
    Eur J Pharmacol; 2010 Aug; 640(1-3):250-6. PubMed ID: 20465996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose lowering efficacy of the aqueous stem bark extract of Trema orientalis (Linn) Blume in normal and streptozotocin diabetic rats.
    Dimo T; Ngueguim FT; Kamtchouing P; Dongo E; Tan PV
    Pharmazie; 2006 Mar; 61(3):233-6. PubMed ID: 16599266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glibenclamide treatment blocks metabolic dysfunctions and improves vagal activity in monosodium glutamate-obese male rats.
    Franco CCS; Prates KV; Previate C; Moraes AMP; Matiusso CCI; Miranda RA; de Oliveira JC; Tófolo LP; Martins IP; Barella LF; Ribeiro TA; Malta A; Pavanello A; Francisco FA; Gomes RM; Alves VS; Moreira VM; Rigo KP; Almeida DL; de Sant Anna JR; Prado MAAC; Mathias PCF
    Endocrine; 2017 May; 56(2):346-356. PubMed ID: 28233096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
    Abdel-Zaher AO; Ahmed IT; El-Koussi AD
    Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
    Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
    J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
    Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
    Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Allium sativum extract on the hypoglycemic activity of glibenclamide: an approach to possible herb-drug interaction.
    Poonam T; Prakash GP; Kumar LV
    Drug Metabol Drug Interact; 2013; 28(4):225-30. PubMed ID: 24114899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.